Doxercalciferol
C08211 · TSA 840 · 1α-OHD2 · Hectorol · ERCALCIDOL · Docalcitol · 1ALPHA-OH-D2 · Doxecalciferol
Identifikatoren & physikalische Daten
| CAS No. | 54573-75-0 |
|---|---|
| Summenformel | C28H44O2 |
| Durchschnittliche Molmasse | 412,6 g/mol |
| Monoisotopische Masse | 412,33413065 g/mol |
| SMILES | C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)/C=C/[C@H](C)C(C)C)CC[C@@H]23)C[C@@H](O)C[C@@H]1O |
| InChIKey | HKXBNHCUPKIYDM-CGMHZMFXSA-N |
| PubChem CID | 5281107 |
| ChEMBL | CHEMBL1200810 |
| ChEBI | CHEBI:4712 |
| EC No. | 643-005-9 |
| DTXSID | DTXSID1034214 |
Chemische & physikalische Eigenschaften
| XLogP | 6,3 |
|---|---|
| Polarare Oberfläche (TPSA) | 40,5 |
| H-Brücken-Donoren | 2 |
| H-Brücken-Akzeptoren | 2 |
| Frei drehbare Bindungen | 5 |
| Schwere Atome | 30 |
| Formalladung | 0 |
| Komplexität | 712 |
| Lipide | Lipids -> Sterol Lipids [ST] -> Secosteroids [ST03] -> Vitamin D2 and derivatives [ST0301] |
| Löslichkeit | Relatively insolubleDMSO: >10mg/mL |
| Human Drugs | FDA approved drugs -> Active ingredient |
| Schmelzpunkt | 138-140°C |
| Siedepunkt | 538.7±50.0 °C(Predicted) |
| Dichte | 1.01±0.1 g/cm3(Predicted) |
| Lagerbedingungen | Sealed in dry,Store in freezer, under -20°C |
| Aggregatzustand | White crystalline solid |
| pKa (Säurekonstante) | 14.43±0.40(Predicted) |
| Farbe | White to Almost white |
| InChIKey | HKXBNHCUPKIYDM-CGMHZMFXSA-N |
| SMILES | [C@@H]1(O)C/C(=C/C=C2\CCC[C@@]3(C)[C@@]\2([H])CC[C@@H]3[C@H](C)/C=C/[C@H](C)C(C)C)/C(=C)[C@@H](O)C1 |
| CAS Datenbank | 54573-75-0(CAS DataBase Reference) |
| EPA chemische Informationen | Doxercalciferol (54573-75-0) |
Sicherheit & Vorschriften
| GHS-Einstufung | DangerH300 (100%): Fatal if swallowed [Danger Acute toxicity, oral]P264, P270, P301+P316, P321, P330, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 51 reports by companies from 2 notifications to the ECHA C&L Inventory. |
|---|---|
| Hazard Classes and Categories | Acute Tox. 1 (100%) |
| Drug Induced Liver Injury | Drug Induced Liver Injury Rank (DILIrank 2.0)DoxercalciferolAmbiguous-DILI-concern3Adverse reactionsDOI:10.1016/j.drudis.2016.02.015 |
| Wassergefährdungsklasse (WGK) | 3 |
| UN-Transportnummer | UN 2811 6.1 / PGIII |
| Zollcode | 2936299055 |
| RTECS-Nr. | VS2950000 |
| R-Sätze (R) | 28 |
| Toxizität | LD50 orally in rats: 3.5-6.5 mg/kg (Sjden) |
| Gefahrensymbole | T+ |
| Sicherheitshinweise (S) | 28-36/37-45 |
| Lagerklasse | 6.1A - Combustible acute toxic Cat. 1 and 2very toxic hazardous materials |
| Gefahrenklasse | Acute Tox. 1 Oral |
Anwendungen & Verwendung
Beschreibung
Doxercalciferol is a synthetic vitamin D2 analog introduced in the US as Hectorol for the treatment of secondary hyperparathyroidism (SHPT) in patients with end-stage renal failure. It is actually 1-alpha-hydroxyvitamin D2 (one-alpha- D2) and can be synthesized by direct hydroxylation of vitamin D2 tosylate or in 5 steps from ergosterol. Doxercalciferol itself is inactive until metabolized by the liver into active 1,24-dihydroxyvitamin D2, showing a pharmacokinetic profile similar to calcitriol. During placebo-controlled clinical trials, patients with moderate to severe SHPT were treated with 1-alpha-D2 (10 μg doses) for 16 to 24 weeks; in 9 patients out of 10, blood levels of parathyroid hormone were considerably reduced, so maintaining a good control of the parathyroid hyperplasia. Moreover, only a moderate tendency to raise calcium and phosphate was observed. Doxercalciferol is orally-active and less toxic than other vitamin D analogs like alfacalcidol; it shows differentially controlled effects and has an improved safety profile compared to calcitriol.
Verwenden
Synthetic vitamin D prohormone. A new active Vitamin D analog which inhibits growth of human neuroblastoma. Antihyperparathyroid